CEG-AgNPs Ameliorates DMBA-Induced Mammary Carcinogenicity by Alleviating Cytokines Expression

lt;bgt;Background and Objective:lt;/bgt; For more than a decade, breast cancer has been one of the most common forms of cancer among women around the world. The present article aimed to evaluate the protective activity of CEG-AgNPs against DMBA-induced mammary carcinoma.lt;bgt;Materials and Methods:lt;/bgt; In this experimental study, green synthesis and characterization of CEG-AgNPs were carried as well as IClt;subgt;50lt;/subgt; against Mcf7 cell line and LDlt;subgt;50lt;/subgt; on mice were evaluated. A total of 24 adult albino mice were divided into four groups six rats in each. Group I was given an equal amount of distilled water, group II was received 80 mg kglt;supgt;lt;/supgt;lt;supgt;1lt;/supgt; b.wt., DMBA for 4 weeks, groups III and IV were treated with CEG-AgNPs (28.1 and 70.25 mg kglt;supgt;lt;/supgt;lt;supgt;1lt;/supgt;) from the 5th week of DMBA administration for 4 weeks, respectively.lt;bgt;Results:lt;/bgt; CEG-AgNPs were approximately 42.32±9.52 nm with a negative zeta potential of -17.44. It is IClt;subgt;50lt;/subgt; against the Mcf7 cell line and LDlt;subgt;50lt;/subgt; is equal to 82.76 μg mLlt;supgt;lt;/supgt;lt;supgt;1lt;/supgt; and 1405 mg kglt;supgt;lt;/supgt;lt;supgt;1lt;/supgt; b.wt., A significant normalization in plasma ALT, AST, AST and LDH as well as mammary MDA, TNF-α, IL-6, P53, SOD, GPx and GSH levels have been observed in CEG-AgNPs treated mice. Oral CEG-AgNPs administration has suppressed VEGF-C gene expression in DMBA-treated mice.lt;bgt;Conclusion:lt;/bgt; The present results, biochemical, histological and MRI results showed that CEG-AgNPs have potent anticancer activity against DMBA-induced mammary carcinoma in mice by inducing the biosynthesizes of antioxidant biomarkers and suppression of cytokines gene expression.